Novel Combination Targeting BCR::ABL1 in Ph+ ALL With TKIs, STAMP-Inhibitor Is Very Well ToleratedByAmi Ali, PharmD, BCOP,Elham Mowlavi, PharmD Candidate,Arghavan Zolfaghari, PharmD Candidate,Jose Tinajero, PharmD, BCOPAugust 9th 2023Pharmacists will play a significant role in TKI adherence rates among patients.